Status:
COMPLETED
Factor VIIa in Acute Intracerebral Haemorrhage
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Acquired Bleeding Disorder
Intracerebral Haemorrhage
Eligibility:
All Genders
20+ years
Phase:
PHASE2
Brief Summary
This trial is conducted in Japan. The purpose of this trial is to evaluate the safety and preliminary efficacy of Activated Recombinant Factor VII (NN-007) in patients with acute intracerebral haemorr...
Eligibility Criteria
Inclusion
- Spontaneous ICH
Exclusion
- Time of ICH onset \> 3 hours
- Patients with secondary ICH
- Pre-existing disability
- Hemophilia
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2007
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT00266006
Start Date
January 1 2006
End Date
April 1 2007
Last Update
November 18 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Tokyo, Japan, 1000005